OS
Fig. 1 · Panel E
Panel E 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Nobuhiko Oridate, Shunji Takahashi, Kaoru Tanaka, Yasushi Shimizu, Yasushi Fujimoto, Koji Matsumoto, Tomoya Yokota, Tomoko Yamazaki, Masanobu Takahashi, Tsutomu Ueda, Nobuhiro Hanai, Hironori Yamaguchi, Hiroki Hara, Tomokazu Yoshizaki, Ryuji Yasumatsu, Masahiro Nakayama, Kiyoto Shiga, Takashi Fujii, Kenji Mitsugi, Kenichi Takahashi, Nijiro Nohata, Burak Gumuscu, Nati Lerman, Makoto Tahara
Int J Clin Oncol 29(12) 1825-1839
BACKGROUND: Previously reported results from phase III KEYNOTE-048 demonstrated similar or improved overall survival (OS) with pembrolizumab or pembrolizumab-chemotherapy versus cetuximab-chemotherapy (EXTREME) in Japanese patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). We report results in Japanese patients from KEYNOTE-048 after 5 years of follow-up. METHODS: Patients with R/M HNSCC of the oropharynx, oral cavity, hypopharynx, or larynx were randomly assigned 1:1:1 to pembrolizumab, pembrolizumab-chemotherapy, or EXTREME. Primary endpoints were OS and progression-free survival. Efficacy was evaluated in the programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 20, PD-L1 CPS ≥ 1, and total Japanese populations. RESULTS: In Japan, 67 patients were enrolled (pembrolizumab, n = 23; pembrolizumab-chemotherapy, n = 25; EXTREME, n = 19). Median follow-up was 71.0 months (range, 61.2-81.5); data cutoff, February 21, 2022. 5-year OS rates with pembrolizumab versus EXTREME were 35.7% versus 12.5% (hazard ratio [HR] 0.38; 95% CI 0.13-1.05), 23.8% versus 12.5% (HR 0.70; 95% CI 0.34-1.45), and 30.4% versus 10.5% (HR 0.54; 95% CI 0.27-1.07) in the PD-L1 CPS ≥ 20, CPS ≥ 1, and total Japanese populations, respectively. 5-year OS rates with pembrolizumab-chemotherapy versus EXTREME were 20.0% versus 14.3% (HR 0.79; 95% CI 0.27-2.33), 10.5% versus 14.3% (HR 1.18; 95% CI 0.56-2.48), and 8.0% versus 12.5% (HR 1.11; 95% CI 0.57-2.16) in the PD-L1 CPS ≥ 20, CPS ≥ 1, and total Japanese populations, respectively. CONCLUSION: After 5 years of follow-up, pembrolizumab and pembrolizumab-chemotherapy showed long-term clinical benefits; results further support these treatments as first-line options for Japanese patients with R/M HNSCC. CLINICAL TRIAL REGISTRATION: NCT02358031.
2 个 Figure · 4 个 KM 面板
Fig. 1 Pembrolizumab versus EXTREME in the A PD-L1 CPS ≥ 20, B PD-L1 CPS ≥ 1, and C total Japanese populations at long-term follow-up and pembrolizumab-chemotherapy versus EXTREME in the D PD-L1 CPS ≥ 20, E PD-L1 CPS ≥ 1, and F total Japanese populations. a From the product-limit (Kaplan–Meier) method for censored data. b On the basis of a Cox proportional hazards regression model with the Efron method of tie handling with treatment as a covariate. CI confidence interval, CPS combined positive score, HR hazard ratio, OS overall survival, PD-L1 programmed cell death ligand 1
Fig. 2 Pembrolizumab versus EXTREME in the A PD-L1 CPS ≥ 20, B PD-L1 CPS ≥ 1, and C total Japanese populations at long-term follow-up and pembrolizumab-chemotherapy versus EXTREME in the D PD-L1 CPS ≥ 20, E PD-L1 CPS ≥ 1, and F total Japanese populations. a From the product-limit (Kaplan–Meier) method for censored data. b On the basis of a Cox proportional hazards regression model with the Efron’s method of tie handling with treatment as a covariate. CI confidence interval, CPS combined positive score, HR hazard ratio, PD-L1 programmed cell death ligand 1, PFS progression-free survival
这些图片未产生 KM 曲线结果,不在主页面重复展示。